NCT01155583: Phase 1/2: Low-Dose Azacitidine, Lenalidomide & Low-Dose Dexamethasone in RRMM Myeloma
NCT01155583: Phase 1/2: Low-Dose Azacitidine, Lenalidomide, and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma
Low-Dose Azacitidine, Lenalidomide, and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma
RATIONALE: Drugs used in chemotherapy, such as azacitidine and dexamethasone, work in different ways to stop the growth of cancer cells either by killing the cells or by stopping them from dividing. Biological therapies, such as lenalidomide, may stimulate the immune system in different ways and stop cancer cells from growing. Giving azacitidine together with lenalidomide and dexamethasone may kill more cancer cells.
PURPOSE: This phase I/II trial is studying the side effects and best dose of azacitidine when given together with lenalidomide and low-dose dexamethasone in treating patients with relapsed or refractory multiple myeloma.
Case Comprehensive Cancer Center
United States, Ohio
ClinicalTrials.gov Identifier: NCT01155583
Official Title: A Phase I/II Trial Of Very Low to Low-Doses of Continuous Azacitidine in Combination With Standard Doses of Lenalidomide and Low-Dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
First Posted : July 2, 2010
Click here for details on Clinicaltrials.gov
Other: DNA methylation analysis
Other: gene expression analysis
Other: bone marrow aspiration
Other: immunohistochemistry staining method
Other: reverse transcriptase-polymerase chain reaction
Other: flow cytometry
A phase I/II trial of very low to low-dose continuous azacitidine in combination with standard doses of lenalidomide and low-dose dexamethasone in patients with relapsed or refractory multiple myeloma.
Meeting Abstract | 2015 ASCO Annual Meeting I
Conclusions: AZA was well tolerated up to target 50mg/m2 SC twice a week in combination with len-dex . Inverse correlation of CDA activity with response suggests AZA contributed to benefit and supports development of the HPLC assay to select patients for aza nucleoside treatment and guide development of CDA inhibitors.
MYELOMA - THERAPY, EXCLUDING TRANSPLANTATION| NOVEMBER 16, 2012
Very Low to Low Doses of Continuous Azacitidine in Combination with Standard Doses of Lenalidomide and Low-Dose Dexamethasone (Rd) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Interim Results of a Phase I/II Study
Azacitidine was generally well tolerated up to the target maximal dose of 50mg/m2SC twice a week (BIW) in combination with Rd given to 4 out of 6 patients required for establishing the phase 2 dose. Encouraging response rates in refractory MM correlated with low plasma activity of the azacitidine inactivating enzyme CDA found predominantly in women. Results support development of azacitidine in RRMM and argue for testing combination with the competitive inhibitor of CDA, tetrahydrouridine. Until then, dose escalation in non-responding but tolerating patients will be explored.